Use of erythropoietin in ophthalmology: a review

Feizi, Sepehr; Alemzadeh-Ansari, Mohammad-Hasan; Karimian, Farid; Esfandiari, Hamed

doi:10.1016/j.survophthal.2021.06.002

Cited by 14 publications

(22 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several ocular and systemic contraindications have been described for erythropoietin administration, including the presence of any hematological and solid malignancy, history of thrombi-embolic events and epilepsy, polycythemia, high systemic blood pressure, iris and retinal neovascularization, and proliferative diabetic retinopathy [ 11 ]. This case report along with previous studies suggests that topical erythropoietin administered in eyes with a history of conjunctival SCC can increase the risk of tumor recurrence with intraocular extension.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Erythropoietin, a glycoprotein hormone, regulates hematopoiesis by stimulating the differentiation and proliferation of hematopoietic stem cells and inhibiting their apoptosis [ 11 ]. Erythropoietin and its receptor are localized in different tissues such as vascular endothelium and retina, indicating that this hormone is important for maintaining their physiological homeostasis [ 11 ]. Recently, we demonstrated the efficacy of erythropoietin in the management of scleral necrosis caused by different etiologies including ocular procedures, chemical burns, and collagen vascular disease [ 12 , 13 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recurrent Conjunctival Squamous Cell Carcinoma and Intraocular Tumor Extension after Topical Erythropoietin: A Case Report

Feizi

Esfandiari

2022

Case Rep Ophthalmol

Self Cite

View full text Add to dashboard Cite

Topical erythropoietin has been recently introduced for the treatment of avascular conjunctival and scleral lesions. Before this treatment can be routinely used, however, its safety profile and contraindications should be determined. Herein, we report a case of recurrent conjunctival squamous cell carcinoma (SCC) and intraocular tumor extension after treatment with topical erythropoietin for excisional biopsy-induced scleral necrosis. An 87-year-old man underwent excisional biopsy for a conjunctival leukoplakic mass. Histological examination showed a well-differentiated SCC on the postoperative day 10. All borders of the specimen were reported to be involved with tumoral cells. The patient did not receive further surgical intervention or topical mitomycin since he developed surgically induced scleral necrosis on the postoperative day 14. Topical erythropoietin 3,000 IU/mL was started every 6 h, and avascular scleral lesion healed over 21 days of treatment with topical erythropoietin. However, 4 months after complete improvement, the tumor recurred with extension into the anterior chamber. Ultrasound biomicroscopy showed the involvement of sclera, iris root, and ciliary body with blunting of the anterior chamber angle. Orbital extension was not detected in magnetic resonance imaging. Topical erythropoietin administered in eyes with a history of conjunctival SCC could be linked to tumor recurrence and intraocular invasion. We recommend avoiding topical erythropoietin in eyes with existing conjunctival SCC or a previous history of conjunctival SCC that was incompletely removed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recurrent Conjunctival Squamous Cell Carcinoma and Intraocular Tumor Extension after Topical Erythropoietin: A Case Report

Feizi

Esfandiari

2022

Case Rep Ophthalmol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Erythropoietin is a hormone mostly produced by adult kidneys that has been shown to protect the cells of the retina from excessive oxidation and exposure to strong light. This hormone exhibits antioxidant, anti-inflammatory, neuroprotective, angiogenic, and anti-apoptotic effects [ 143 ]. There is also a report that the improvement in vision is only transient after the intravenous administration of EPO in combination with methylprednisone, and a single study has shown that the efficacy of EPO in methanol-induced optic neuropathy was not observed in the late cases of the disease [ 142 , 143 , 144 ].…”

Section: Treatment Optionsmentioning

confidence: 99%

Toxic and Nutritional Optic Neuropathies—An Updated Mini-Review

Baj

Forma

Kobak

et al. 2022

IJERPH

View full text Add to dashboard Cite

Optic neuropathies constitute a group of conditions with various etiologies and might be caused by different factors; we can distinguish the genetic and acquired causes of optic neuropathies. Even though the symptoms are not highly specific, this condition is primarily characterized by unilateral or bilateral vision loss with worsening color detection. The loss may be acute or gradual depending on the causation. In this article, we included a specification of toxic optic neuropathy (TON) mainly triggered by alcohol abuse and also the usage of other substances, including drugs or methanol, as well as intoxication by metals, organic solvents, or carbon dioxide. Nutritional deficiencies, vitamin absorption disorder, and anemia, which usually appear during excessive alcohol intake, and their effect on the etiology of the optic neuropathy have been likewise discussed.

show abstract

“…The global EPO drugs market size has already reached 12 billion USD and is estimated to grow at a compound annual growth rate (CAGR) of 10%, according to the Market Data Forecast. Other EPO-based therapeutic applications are under development, including prevention of dementia, Alzheimer’s disease, Parkinson’s disease, schizophrenia, bipolar disorder, depression, ischemic stroke, traumatic brain injury, diabetes mellitus, acute and chronic lung diseases, various ocular diseases, severe COVID-19, as well as EPO use in the regenerative medicine [ 1 , 3 , 10 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ]. However, the clinical use of the EPO-based medicines is limited due to the pleiotropic nature of this cytokine, leading to serious adverse reactions, such as arterial hypertension, cerebral convulsion/hypertensive encephalopathy, thrombo-embolism, iron deficiency, development of pure red cell aplasia, and the possibility of cancer progression [ 8 , 22 , 23 ].…”

Section: Introductionmentioning

confidence: 99%

Erythropoietin Interacts with Specific S100 Proteins

et al. 2022

View full text Add to dashboard Cite

Erythropoietin (EPO) is a clinically significant four-helical cytokine, exhibiting erythropoietic, cytoprotective, immunomodulatory, and cancer-promoting activities. Despite vast knowledge on its signaling pathways and physiological effects, extracellular factors regulating EPO activity remain underexplored. Here we show by surface plasmon resonance spectroscopy, that among eighteen members of Ca2+-binding proteins of the S100 protein family studied, only S100A2, S100A6 and S100P proteins specifically recognize EPO with equilibrium dissociation constants ranging from 81 nM to 0.5 µM. The interactions occur exclusively under calcium excess. Bioinformatics analysis showed that the EPO-S100 interactions could be relevant to progression of neoplastic diseases, including cancer, and other diseases. The detailed knowledge of distinct physiological effects of the EPO-S100 interactions could favor development of more efficient clinical implications of EPO. Summing up our data with previous findings, we conclude that S100 proteins are potentially able to directly affect functional activities of specific members of all families of four-helical cytokines, and cytokines of other structural superfamilies.

show abstract

Use of erythropoietin in ophthalmology: a review

Cited by 14 publications

References 108 publications

Recurrent Conjunctival Squamous Cell Carcinoma and Intraocular Tumor Extension after Topical Erythropoietin: A Case Report

Recurrent Conjunctival Squamous Cell Carcinoma and Intraocular Tumor Extension after Topical Erythropoietin: A Case Report

Toxic and Nutritional Optic Neuropathies—An Updated Mini-Review

Erythropoietin Interacts with Specific S100 Proteins

Contact Info

Product

Resources

About